1 published article · Updated continuously
5 trials tracked for neurogenic orthostatic hypotension: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 50 citations.
Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Midodrine has been shown to result in a reduction of the Depression Score (Beck Depression Inventory-II) by values ranging from -3.5 to -7.8 1.
Droxidopa was evaluated for its impact on orthostatic hypotension symptoms; however, it did not produce statistically significant improvements in OHQ composite scores (p=0.438), OHDAS scores (p=0.554), or OHSA composite scores (p=0.198) 2. Droxidopa was also evaluated in a larger cohort of 350 patients 3.
AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
